Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 19, 2013The American Journal of Gastroenterology

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

View Full Paper
Ask AI
Bookmark
Share

Authors

NCNiels Vande CasteeleUniversity of San DiegoAGAnn GilsNovartis (Switzerland)SSSharat SinghMirati Therapeutics (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Casteele et al. (2013) studied this question.

synapsesocial.com/papers/6a72a8d25d37378ac1df5831https://doi.org/10.1038/ajg.2013.12
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease2012 · 104 citations
  2. 2Detection of infliximab levels and anti‐infliximab antibodies: a comparison of three different assays2012 · 209 citations
  3. 3Activation of natural regulatory T cells by IgG Fc–derived peptide “Tregitopes”2008 · 390 citations
  4. 4Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis2012 · 335 citations
  5. 5Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up2011 · 787 citations